Top Markets
Coin of the day
Chordia Therapeutics Inc. Chordia Therapeutics Inc.

Chordia Therapeutics Inc.

190A
Rank in Stocks #26481
Chordia Therapeutics Inc., a biotech company, engages in research and... Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan.
Share Price
$0.53499835
Market Cap
$40.24M
Change (1 day)
2.50%
Change (1 year)
-58.07%
Country
JP
Trade Chordia Therapeutics Inc. (190A)

Category

Earnings for Chordia Therapeutics Inc. (190A)
Earnings in 2026 TTM: 0
According to Chordia Therapeutics Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Chordia Therapeutics Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$1.95B -
NL
$1.61B -
AU
- -
CH
$-3.09B -
US